Key result
Renal denervation is linked to a ~15 g reduction in left ventricular mass at 24 months.
Why the study?
To evaluate the long-term effects of renal denervation on left ventricular mass and inflammatory markers in patients with resistant hypertension.
Does renal denervation improve left ventricular mass and inflammatory markers in patients with resistant hypertension?
Cohort (n=41)
No
Does renal denervation improve left ventricular mass and inflammatory markers in patients with resistant hypertension?
Renal denervation in patients with resistant hypertension is associated with long-term reductions in left ventricular mass and systemic inflammatory markers at 2 years.
Renal denervation was associated with reduced LV mass and inflammation; hypothesis-generating for resistant hypertension and needs randomized confirmation.
Aim. To study the long-term effect of renal denervation (RDN) on left ventricular mass (LVM) and inflammatory markers in resistant hypertensive patients. Material and methods. Forty-one patients with resistant hypertension and 24-h blood pressure (BP) 158,7±15,8/87,3+14,6 mmHg, aged 56,6+10,2 years, were enrolled in the study and undergone RDN. Mean 24-h BP, left ventricular mass (transthoracic echocardiography), high sensitivity C-reactive protein (hsCRP), interleukin- 1β (IL1β), IL-6, IL-10) and tumor necrosis factor alpha (TNF- α) were assessed at baseline and 2 years after the RDN. Results. A baseline prevalence of left ventricular hypertrophy (LVH) was 90,2%. Two years after RDN LVM and interventricular septum (IVS) decreased significantly (p<0.05 for both). Decrease in myocardial mass (∆LVM >0 g) was documented in 24 patients. The regression of LVM was accompanied by a significant decrease in levels of inflammatory markers — hsCRP by 38,3% (p=0,031), TNF-α by 60,7% (p=0,009), IL- 1β — by 71,1% (p=0,001), and IL-10 by 58,2% (p=0,001). In patients in the absence of LVM regression only TNF-α decreased significantly (-68,8%, p=0,001). There was no correlation between changes of LVM and the inflammatory markers at 24 months after RDN. Conclusion. The RDN in RH patients may have long-term cardioprotective effect in terms of significant regress of LVH, which may be partly attributed to the regress in systemic or myocardial inflammation.
No takes yet. Share an insight, caveat, or question.
Ситкова et al. (2021) conducted a cohort in Resistant hypertension (n=41). Renal denervation vs. Baseline was evaluated on Left ventricular mass (p=0.048). Renal denervation significantly reduced left ventricular mass from 269.9 g to 254.6 g (p=0.048) and decreased inflammatory markers like hsCRP by 38.3% at 24 months in resistant hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: